KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy (Q84894126)
Jump to navigation
Jump to search
scientific article published on 02 September 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy |
scientific article published on 02 September 2011 |
Statements
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy (English)
F Kullmann
A Hartmann
R Stöhr
H Messmann
M M Dollinger
J Trojan
M Fuchs
S Hollerbach
J Harder
M Troppmann
A Kutscheidt
2 September 2011